Navigation Links
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
Date:6/15/2009

PITTSBURGH, Pennsylvania, and JERUSALEM, Israel, June 15 /PRNewswire/ -- The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study.

The phase III study is assessing the safety and efficacy of StemEx(R), an investigational product derived from stem cells, as an alternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymphoma. StemEx is a graft of expanded stem/progenitor cells taken from a single unit of umbilical cord blood and then transplanted in combination with non-expanded cells from the same unit.

"I am extremely pleased UPCI has the opportunity to be a part of this study," said Mounzer Agha, M.D., clinical director of UPCI's Hematopoietic Stem Cell Transplant Program. "Using umbilical cord blood stem cells instead of a traditional bone marrow transplant opens tremendous treatment possibilities for patients with diseases like leukemia and lymphoma."

Bone marrow transplantation is a life-saving treatment for many types of leukemia and lymphoma. However, more than half the number of patients in need of a transplant can't find matching bone marrow donors. Cord blood could be an alternative of choice.

Previous research has shown that umbilical cord blood stem cells offer a viable therapeutic option for leukemia and lymphoma patients without the necessity of a matched donor. Umbilical cord blood has two important advantages - it is a readily available source for stem cells and it has a lower matching requirement for patients. With StemEx(R), the cord blood unit is enriched with stem cells, which are critical for a successful transplantation.

"We are pleased to work with the able and highly experienced team at UPCI led by Dr. Agha. They join an extraordinary group of cord blood cancer centers currently recruiting patients for the ExCell trial. Everyone on the international ExCell clinical team shares the same goal - to validate the therapeutic potential of StemEx as a treatment for blood cancers," said David Snyder, M.D., vice president of clinical development at Gamida Cell.

About UPCI

Founded in 1984, the University of Pittsburgh Cancer Institute became a National Cancer Institute (NCI)-designated Comprehensive Cancer Center in 1990. UPCI, the only cancer center in western Pennsylvania with this elite designation, serves the region's population of more than 6 million. Presently, UPCI receives a total of $154 million in research grants and is ranked 10th in funding from the NCI.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures.

    CONTACT:

    Courtney McCrimmon
    Wendy Zellner
    UPMC Media Relations
    PHONE: +1-412-647-3555
    E-MAIL: McCrimmonCP@upmc.edu
            ZellnerWL@upmc.edu

    CONTACT: Marjie Hadad
    Gamida Cell
    PHONE: +972-54-536-5220
    E-MAIL: marjie@gamida-cell.com



'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
2. BARC Central Laboratory Joins Alzheimers Association Research Roundtable
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Photos: Sentara Joins 4 U.S. Hospitals in International TARGIT Breast Cancer Trial
5. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
6. Vincent W. Renz Joins NewCardio as President
7. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
8. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology:
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... ... an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for ... not-for-profit Catholic health care system that’s partnering with Intel on value-based health benefits ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO ... Garrett will focus on contract negotiations, corporate strategy and healthcare data law. Additional ... best practices in data breaches for the Part D Star Rating improvement and ...
(Date:2/11/2016)... ... 11, 2016 , ... AccuVein Inc. announces the Infusion Nurses ... Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ), ... market, facilitates adherence to this standard with its easy to use, widely deployed ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most ... DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel of experts ... panel’s goal is to recognize and promote technology entrepreneurship. , The survey was ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan Scientific, ... gauges used in physical therapy, occupational therapy and sports medicine clinics, hospitals, universities ... exercise and therapy, introduces its new microFET Digital Pinch Gauge. , Hoggan ...
Breaking Medicine News(10 mins):